Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
Create a narrative
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Alphabet
BL
BlackGoat
Community Contributor
Alphabet: The Under-appreciated Compounder Hiding in Plain Sight
Summary Google trades at ~18× forward earnings; the cheapest among the Magnificent 7 Market is too focused on AI threats to Search and antitrust noise Meanwhile, Google is executing across AI, Cloud, and YouTube Key AI differentiator: unmatched distribution across 3B+ users via Search, Gmail, YouTube, Android, Chrome, and Cloud Quietly building a world-class AI infrastructure behind the scenes; including proprietary TPUs and a vertically integrated stack YouTube generated $8.93B in Q1 ad revenue (up 10% YoY); subscriptions hit 270M Google Cloud revenue up 28% YoY to $12.3B; now profitable Optionality from long-term bets like Waymo, DeepMind, and Verily Risk/reward is compelling; a strong candidate to beat the market long term Overview Despite being part of the "Magnificent Seven," Google’s stock lags due to perceived risks around disruption of its Search business from AI competitors and mounting antitrust concerns. But under the hood, Google has quietly built one of the most compelling setups in tech: with deep AI leadership, multiple high-growth businesses, and optionality from long-term moonshots like Waymo.
View narrative
US$282.83
FV
32.8% undervalued
intrinsic discount
9.00%
Revenue growth p.a.
Set Fair Value
24
users have liked this narrative
3
users have commented on this narrative
62
users have followed this narrative
Updated
narrative
Planet Labs PBC
AN
andreas_eliades
Community Contributor
Planet Labs: At The Heart Of The Emerging New Space Boom
Planet Labs leads the EO market with the largest satellite constellation, poised to capitalize on the growing demand for Earth Observation and geospatial data from companies and governments. Plunging space launch and GPU computation costs combined with advancements in CubeSat and AI technologies are boosting the utility of Earth Observation data.
View narrative
US$11.31
FV
45.4% undervalued
intrinsic discount
30.00%
Revenue growth p.a.
Set Fair Value
18
users have liked this narrative
1
users have commented on this narrative
67
users have followed this narrative
New
narrative
Exxon Mobil
AG
Agricola
Community Contributor
Exxon in Guyana 5 year forecast Low $135 to High $189
Previous mistake rectified. So as pointed out in the comments, Chevron won the Hess bid (rather than Exxon) and took a large portion of the Stabroek block.
View narrative
US$174.00
FV
37.0% undervalued
intrinsic discount
12.97%
Revenue growth p.a.
Set Fair Value
4
users have liked this narrative
4
users have commented on this narrative
17
users have followed this narrative
Updated
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
i-80 Gold
AN
AnalystConsensusTarget
Consensus Narrative from 7 Analysts
Granite Creek, Ruby Hill, And Lone Tree Will Advance Gold Production
Key Takeaways The development and strategic investments in gold projects are expected to significantly boost i-80 Gold's future production and revenue. Improved processing capabilities and strategic project de-risking are anticipated to enhance operational margins and stabilize future earnings.
View narrative
CA$2.24
FV
64.3% undervalued
intrinsic discount
80.78%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
9
users have followed this narrative
11 days ago
author updated this narrative
PCAR
Companhia Brasileira De Distribuicao
AN
AnalystConsensusTarget
Consensus Narrative from 11 Analysts
Restructuring And E-Commerce Expansion Will Strengthen Future Position
Key Takeaways Successful turnaround project and strategic expansion initiatives enhance margins and drive potential revenue and profit growth. E-commerce and premium formats expansion, coupled with retail media growth, improve market penetration and profitability.
View narrative
R$3.21
FV
8.8% overvalued
intrinsic discount
6.61%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
2
users have followed this narrative
11 days ago
author updated this narrative
Sangamo Therapeutics
AN
AnalystConsensusTarget
Consensus Narrative from 5 Analysts
Neurology IND And Fabry Agreements Will Transform Treatment
Key Takeaways Strategic partnerships and collaborations position Sangamo as a key player, enhancing revenue potential through non-dilutive capital and licensing agreements. Cost reduction initiatives and a clear path to accelerated approval for treatments may lead to improved net margins and early revenue generation.
View narrative
US$4.10
FV
86.3% undervalued
intrinsic discount
52.35%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
1
users have commented on this narrative
14
users have followed this narrative
11 days ago
author updated this narrative
SIG
AN
AnalystConsensusTarget
Consensus Narrative from 7 Analysts
Modernization And UK Interiors Upgrades Will Fuel Operational Recovery
Key Takeaways Targeted investments in modernization and digitalization are expected to improve margins and positively impact revenue and net profits. New management aims to enhance operations and return the U.K. Interiors segment to profitability, boosting overall earnings potential.
View narrative
UK£0.17
FV
15.9% undervalued
intrinsic discount
2.99%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
1
users have commented on this narrative
2
users have followed this narrative
11 days ago
author updated this narrative
ATN International
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
Fiber Network Expansion And Enterprise Focus Will Open New Frontiers
Key Takeaways Transitioning to fiber-based services and network expansion will enhance revenue growth, net margins, and operational efficiency. Strategic focus on enterprise revenue streams and government grants aim to boost cash flow and shareholder value with lower capital intensity.
View narrative
US$29.00
FV
41.4% undervalued
intrinsic discount
1.45%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
2
users have followed this narrative
11 days ago
author updated this narrative
Amarin
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
I Foresee 49 Approvals Driving European And Global Market Expansion
Key Takeaways Expanded regulatory approvals and commercialization in 49 markets support future revenue growth, particularly through focused expansion in Europe and worldwide. Strong intellectual property and financial stability underpin strategic marketing, expected to enhance revenue and profitability, especially for VASCEPA in high-risk cardiovascular populations.
View narrative
US$10.50
FV
44.4% overvalued
intrinsic discount
-2.98%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
1
users have commented on this narrative
10
users have followed this narrative
11 days ago
author updated this narrative
Telos
AN
AnalystConsensusTarget
Consensus Narrative from 5 Analysts
DMDC And TSA PreCheck Expansion Will Fuel Future Success
Key Takeaways Expansion of programs like TSA PreCheck and DHS projects is poised to drive significant revenue and cash flow growth. Favorable shift to high-margin Security Solutions will enhance gross margins and strengthen financial health.
View narrative
US$3.85
FV
35.6% undervalued
intrinsic discount
33.76%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
1
users have commented on this narrative
5
users have followed this narrative
11 days ago
author updated this narrative
Silence Therapeutics
AN
AnalystConsensusTarget
Consensus Narrative from 7 Analysts
ALPACAR-360 Success And AstraZeneca Collaboration Will Advance siRNA Pipeline
Key Takeaways The company's strategic partnerships and collaborations could reduce financial risk and enhance revenue growth through shared commercialization and milestone payments. Successful study results and orphan drug designation might lead to dominance in niche markets, improving future earnings and net margins.
View narrative
US$32.37
FV
80.9% undervalued
intrinsic discount
16.44%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
1
users have commented on this narrative
10
users have followed this narrative
11 days ago
author updated this narrative
Alta Equipment Group
AN
AnalystConsensusTarget
Consensus Narrative from 5 Analysts
IIJA Spending And Automation Will Lift Heavy Equipment Demand
Key Takeaways Elevated infrastructure spending and optimized operational initiatives are expected to boost Alta's revenue and profitability in key segments. Strategic growth through M&A and investments in automation promise long-term revenue growth and earnings stability.
View narrative
US$10.46
FV
28.7% undervalued
intrinsic discount
2.57%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
1
users have commented on this narrative
5
users have followed this narrative
11 days ago
author updated this narrative
Value any company in seconds
Popular companies